EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Navigating the Challenges of Shared Decision‐Making in Amyloid Immunotherapy for Alzheimer's Disease

Grâce François iD, Robin Michalon iD, Thomas Tannou iD, Philippe Damier iD, Sonia Desmoulin iD, Thibaud Lebouvier iD

European Journal of Neurology · 2026-11 · 33 (11)

DOI: 10.1111/ene.70800 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 02.11.2026. Verfasst von Grâce François und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lille Neuroscience & Cognition, UMR-S 1172, LabEx DISTALZ, Université de Lille, Inserm, CHU Lille, Lille, France. Hauptthemen laut MEDLINE: Alzheimer Disease, Decision Making, Shared, Immunotherapy, Patient Participation. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti‐amyloid therapies (AATs), such as lecanemab and donanemab, represent a major therapeutic development for early Alzheimer's disease (AD). However, safety risks and uncertainties regarding long‐term effects make treatment decisions complex. These decisions arise when patients remain legally capable of providing informed consent but may experience cognitive vulnerabilities affecting their ability to engage in complex decisions. Shared decision‐making (SDM) is therefore particularly relevant, yet its implementation raises ethical and practical challenges.

Methods

This position paper draws on a multidisciplinary reflection on decision‐making, informed consent, and cognitive vulnerability in early AD and AATs. The authors, with expertise in neurology, geriatrics, law, and history, examined challenges to patient participation and developed a relational framework integrating SDM and supported decision‐making.

Results

Impairments in memory, insight, and executive function, together with cognitive biases, stigma, and the complexity of AAT‐related information, may compromise patient participation despite preserved legal capacity. Formal capacity assessments and improved information delivery may address some difficulties but are unlikely to provide comprehensive support. We propose a relational framework involving assessment of patients' cognitive vulnerabilities, values, preferences, and informational needs; tailored information; and involvement of a patient‐designated care partner to support information exchange, deliberation, and expression of preferences. Consent should be iterative, with safeguards to preserve autonomy and confidentiality, prevent coercion, and avoid excluding socially isolated individuals.

Conclusion

Combining SDM with supported decision‐making may provide an ethical and practical framework for autonomous treatment decisions regarding AATs in early AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseDecision Making, SharedImmunotherapyPatient ParticipationHumansInformed Consent

Stichwörter der Autor:innen

Alzheimer's diseaseanti‐amyloid immunotherapiesconsentshared decision‐makingsupported decision‐making

Autor:innen und Institutionen

  • Lille Neuroscience & Cognition, UMR-S 1172, LabEx DISTALZ, Université de Lille, Inserm, CHU Lille, Lille, France.
  • Recherches en éthique et épistémologie, U1018, Espace de Réflexion Éthique de la Région Île-de-France, Université Paris-Saclay, CESP, INSERM, Gustave Roussy, Villejuif, France.
  • Faculté de médecine, Université de Montréal, Centre de Recherche, Institut de Gériatrie de Montréal, Québec, Canada.
  • Nantes Université, INSERM, CHU Nantes, F-44093 Nantes, Hôpital Fondation Rothschild, Paris, France.
  • Laboratoire Droit et Changement Social, UMR 6297, Nantes Université, CNRS, Nantes, France.

ORCID-Profile: Grâce François, Robin Michalon, Thomas Tannou, Philippe Damier, Sonia Desmoulin, Thibaud Lebouvier

Zitieren

APA

François, G., Michalon, R., Tannou, T., Damier, P., Desmoulin, S., & Lebouvier, T. (2026). Navigating the Challenges of Shared Decision‐Making in Amyloid Immunotherapy for Alzheimer's Disease. European Journal of Neurology, 33(11). https://doi.org/10.1111/ene.70800

Vancouver

François G, Michalon R, Tannou T, Damier P, Desmoulin S, Lebouvier T. Navigating the Challenges of Shared Decision‐Making in Amyloid Immunotherapy for Alzheimer's Disease. European Journal of Neurology. 2026;33(11). doi:10.1111/ene.70800

BibTeX
@article{Franois2026,
  author = {François, Grâce and Michalon, Robin and Tannou, Thomas and Damier, Philippe and Desmoulin, Sonia and Lebouvier, Thibaud},
  title = {Navigating the Challenges of Shared Decision‐Making in Amyloid Immunotherapy for Alzheimer's Disease},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {11},
  doi = {10.1111/ene.70800}
}
Kostenlos starten →